1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2020. CA Cancer J Clin 2020, 70(1):7-30.
2. Herbst RS, Morgensztern D, Boshoff C: The biology and management of non-small cell lung cancer. NATURE 2018, 553(7689):446-454.
3. Dickson RP, Erb-Downward JR, Huffnagle GB: The role of the bacterial microbiome in lung disease. Expert Rev Respir Med 2013, 7(3):245-257.
4. Cameron S, Lewis KE, Huws SA, Hegarty MJ, Lewis PD, Pachebat JA, Mur L: A pilot study using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung cancer. PLOS ONE 2017, 12(5):e177062.
5. Tsay JJ, Wu BG, Badri MH, Clemente JC, Shen N, Meyn P, Li Y, Yie TA, Lhakhang T, Olsen E et al: Airway Microbiota Is Associated with Upregulation of the PI3K Pathway in Lung Cancer. Am J Respir Crit Care Med 2018, 198(9):1188-1198.
6. Lee SH, Sung JY, Yong D, Chun J, Kim SY, Song JH, Chung KS, Kim EY, Jung JY, Kang YA et al: Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. LUNG CANCER 2016, 102:89-95.
7. Cheng C, Wang Z, Wang J, Ding C, Sun C, Liu P, Xu X, Liu Y, Chen B, Gu B: Characterization of the lung microbiome and exploration of potential bacterial biomarkers for lung cancer. Transl Lung Cancer Res 2020, 9(3):693-704.
8. Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Zhou M, Ke H, Shi MM, Qu JM: Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects. INT J CANCER 2018, 142(4):769-778.
9. Greathouse KL, White JR, Vargas AJ, Bliskovsky VV, Beck JA, von Muhlinen N, Polley EC, Bowman ED, Khan MA, Robles AI et al: Interaction between the microbiome and TP53 in human lung cancer. GENOME BIOL 2018, 19(1):123.
10. Apopa PL, Alley L, Penney RB, Arnaoutakis K, Steliga MA, Jeffus S, Bircan E, Gopalan B, Jin J, Patumcharoenpol P et al: PARP1 Is Up-Regulated in Non-small Cell Lung Cancer Tissues in the Presence of the Cyanobacterial Toxin Microcystin. FRONT MICROBIOL 2018, 9:1757.
11. Hosgood HR, Sapkota AR, Rothman N, Rohan T, Hu W, Xu J, Vermeulen R, He X, White JR, Wu G et al: The potential role of lung microbiota in lung cancer attributed to household coal burning exposures. ENVIRON MOL MUTAGEN 2014, 55(8):643-651.
12. Rusch VW, Chansky K, Kindler HL, Nowak AK, Pass HI, Rice DC, Shemanski L, Galateau-Salle F, McCaughan BC, Nakano T et al: The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. J THORAC ONCOL 2016, 11(12):2112-2119.
13. Yu G, Gail MH, Consonni D, Carugno M, Humphrys M, Pesatori AC, Caporaso NE, Goedert JJ, Ravel J, Landi MT: Characterizing human lung tissue microbiota and its relationship to epidemiological and clinical features. GENOME BIOL 2016, 17(1):163.
14. Huang D, Su X, Yuan M, Zhang S, He J, Deng Q, Qiu W, Dong H, Cai S: The characterization of lung microbiome in lung cancer patients with different clinicopathology. AM J CANCER RES 2019, 9(9):2047-2063.
15. Gowing SD, Chow SC, Cools-Lartigue JJ, Chen CB, Najmeh S, Goodwin-Wilson M, Jiang HY, Bourdeau F, Beauchamp A, Angers I et al: Gram-Negative Pneumonia Augments Non-Small Cell Lung Cancer Metastasis through Host Toll-like Receptor 4 Activation. J THORAC ONCOL 2019, 14(12):2097-2108.
16. Hessle CC, Andersson B, Wold AE: Gram-positive and Gram-negative bacteria elicit different patterns of pro-inflammatory cytokines in human monocytes. CYTOKINE 2005, 30(6):311-318.
17. Le Noci V, Guglielmetti S, Arioli S, Camisaschi C, Bianchi F, Sommariva M, Storti C, Triulzi T, Castelli C, Balsari A et al: Modulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance against Lung Metastases. CELL REP 2018, 24(13):3528-3538.
18. Chen J, Pitmon E, Wang K: Microbiome, inflammation and colorectal cancer. SEMIN IMMUNOL 2017, 32:43-53.
19. Luo YH, Wu CH, Wu WS, Huang CY, Su WJ, Tsai CM, Lee YC, Perng RP, Chen YM: Association between tumor epidermal growth factor receptor mutation and pulmonary tuberculosis in patients with adenocarcinoma of the lungs. J THORAC ONCOL 2012, 7(2):299-305.
20. Li M, Deng F, Qian LT, Meng SP, Zhang Y, Shan WL, Zhang XL, Wang BL: Association between human papillomavirus and EGFR mutations in advanced lung adenocarcinoma. ONCOL LETT 2016, 12(3):1953-1958.
21. Jia Z, Bao K, Wei P, Yu X, Zhang Y, Wang X, Wang X, Yao L, Li L, Wu P et al: EGFR activation-induced decreases in claudin1 promote MUC5AC expression and exacerbate asthma in mice. MUCOSAL IMMUNOL 2021, 14(1):125-134.
22. Hall M, Beiko RG: 16S rRNA Gene Analysis with QIIME2. Methods Mol Biol 2018, 1849:113-129.
23. Edgar RC: UPARSE: highly accurate OTU sequences from microbial amplicon reads. NAT METHODS 2013, 10(10):996-998.
24. DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, Huber T, Dalevi D, Hu P, Andersen GL: Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol 2006, 72(7):5069-5072.
25. Douglas GM, Maffei VJ, Zaneveld JR, Yurgel SN, Brown JR, Taylor CM, Huttenhower C, Langille M: PICRUSt2 for prediction of metagenome functions. NAT BIOTECHNOL 2020, 38(6):685-688.
26. Caspi R, Altman T, Billington R, Dreher K, Foerster H, Fulcher CA, Holland TA, Keseler IM, Kothari A, Kubo A et al: The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of Pathway/Genome Databases. NUCLEIC ACIDS RES 2014, 42(Database issue):D459-D471.
27. Parks DH, Tyson GW, Hugenholtz P, Beiko RG: STAMP: statistical analysis of taxonomic and functional profiles. BIOINFORMATICS 2014, 30(21):3123-3124.
28. Friedman J, Alm EJ: Inferring correlation networks from genomic survey data. PLOS COMPUT BIOL 2012, 8(9):e1002687.
29. Chen J, Domingue JC, Sears CL: Microbiota dysbiosis in select human cancers: Evidence of association and causality. SEMIN IMMUNOL 2017, 32:25-34.
30. Druzhinin VG, Matskova LV, Demenkov PS, Baranova ED, Volobaev VP, Minina VI, Apalko SV, Churina MA, Romanyuk SA, Shcherbak SG et al: Taxonomic diversity of sputum microbiome in lung cancer patients and its relationship with chromosomal aberrations in blood lymphocytes. Sci Rep 2020, 10(1):9681.
31. Reinhold L, Mollering A, Wallis S, Palade E, Schafer K, Dromann D, Rupp J, Graspeuntner S, Dalhoff K: Dissimilarity of Airway and Lung Tissue Microbiota in Smokers undergoing Surgery for Lung Cancer. Microorganisms 2020, 8(6).
32. Jin J, Gan Y, Liu H, Wang Z, Yuan J, Deng T, Zhou Y, Zhu Y, Zhu H, Yang S et al: Diminishing microbiome richness and distinction in the lower respiratory tract of lung cancer patients: A multiple comparative study design with independent validation. LUNG CANCER 2019, 136:129-135.
33. Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Zhou M, Ke H, Shi MM, Qu JM: Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects. INT J CANCER 2018, 142(4):769-778.
34. Cameron S, Lewis KE, Huws SA, Hegarty MJ, Lewis PD, Pachebat JA, Mur L: A pilot study using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung cancer. PLOS ONE 2017, 12(5):e177062.
35. Woodard GA, Jones KD, Jablons DM: Lung Cancer Staging and Prognosis. Cancer Treat Res 2016, 170:47-75.
36. Tessema M, Yingling CM, Liu Y, Tellez CS, Van Neste L, Baylin SS, Belinsky SA: Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers. CARCINOGENESIS 2014, 35(6):1248-1257.
37. Inamura K: Clinicopathological Characteristics and Mutations Driving Development of Early Lung Adenocarcinoma: Tumor Initiation and Progression. INT J MOL SCI 2018, 19(4).
38. Marks LB, Saynak M, Christodouleas JP: Stage III vs. stage IV lung cancer: "Crossing a Great Divide". LUNG CANCER 2010, 67(1):1-3.
39. Hosgood HR, Sapkota AR, Rothman N, Rohan T, Hu W, Xu J, Vermeulen R, He X, White JR, Wu G et al: The potential role of lung microbiota in lung cancer attributed to household coal burning exposures. ENVIRON MOL MUTAGEN 2014, 55(8):643-651.
40. Hosgood HR, Mongodin EF, Wan Y, Hua X, Rothman N, Hu W, Vermeulen R, Seow WJ, Rohan T, Xu J et al: The respiratory tract microbiome and its relationship to lung cancer and environmental exposures found in rural china. ENVIRON MOL MUTAGEN 2019, 60(7):617-623.
41. Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Zhou M, Ke H, Shi MM, Qu JM: Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects. INT J CANCER 2018, 142(4):769-778.
42. Harris JK, De Groote MA, Sagel SD, Zemanick ET, Kapsner R, Penvari C, Kaess H, Deterding RR, Accurso FJ, Pace NR: Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci U S A 2007, 104(51):20529-20533.
43. De Luca M, Amodio D, Chiurchiu S, Castelluzzo MA, Rinelli G, Bernaschi P, Calo CF, D'Argenio P: Granulicatella bacteraemia in children: two cases and review of the literature. BMC PEDIATR 2013, 13:61.
44. Haldar K, George L, Wang Z, Mistry V, Ramsheh MY, Free RC, John C, Reeve NF, Miller BE, Tal-Singer R et al: The sputum microbiome is distinct between COPD and health, independent of smoking history. Respir Res 2020, 21(1):183.
45. Parris BA, O'Farrell HE, Fong KM, Yang IA: Chronic obstructive pulmonary disease (COPD) and lung cancer: common pathways for pathogenesis. J THORAC DIS 2019, 11(Suppl 17):S2155-S2172.
46. Rybojad P, Los R, Sawicki M, Tabarkiewicz J, Malm A: Anaerobic bacteria colonizing the lower airways in lung cancer patients. Folia Histochem Cytobiol 2011, 49(2):263-266.
47. Tsay JJ, Wu BG, Badri MH, Clemente JC, Shen N, Meyn P, Li Y, Yie TA, Lhakhang T, Olsen E et al: Airway Microbiota Is Associated with Upregulation of the PI3K Pathway in Lung Cancer. Am J Respir Crit Care Med 2018, 198(9):1188-1198.
48. Popper HH: Progression and metastasis of lung cancer. Cancer Metastasis Rev 2016, 35(1):75-91.
49. Yaku K, Okabe K, Hikosaka K, Nakagawa T: NAD Metabolism in Cancer Therapeutics. FRONT ONCOL 2018, 8:622.
50. Zhu Y, Liu J, Park J, Rai P, Zhai RG: Subcellular compartmentalization of NAD(+) and its role in cancer: A sereNADe of metabolic melodies. Pharmacol Ther 2019, 200:27-41.
51. Yaku K, Okabe K, Hikosaka K, Nakagawa T: NAD Metabolism in Cancer Therapeutics. FRONT ONCOL 2018, 8:622.
52. Jin C, Lagoudas GK, Zhao C, Bullman S, Bhutkar A, Hu B, Ameh S, Sandel D, Liang XS, Mazzilli S et al: Commensal Microbiota Promote Lung Cancer Development via gammadelta T Cells. CELL 2019, 176(5):998-1013.
53. Sheng Q, Du H, Cheng X, Cheng X, Tang Y, Pan L, Wang Q, Lin J: Characteristics of fecal gut microbiota in patients with colorectal cancer at different stages and different sites. ONCOL LETT 2019, 18(5):4834-4844.
54. Tsoi H, Chu E, Zhang X, Sheng J, Nakatsu G, Ng SC, Chan A, Chan F, Sung J, Yu J: Peptostreptococcus anaerobius Induces Intracellular Cholesterol Biosynthesis in Colon Cells to Induce Proliferation and Causes Dysplasia in Mice. GASTROENTEROLOGY 2017, 152(6):1419-1433.
55. Quail DF, Joyce JA: Microenvironmental regulation of tumor progression and metastasis. NAT MED 2013, 19(11):1423-1437.
56. Romano AH, Conway T: Evolution of carbohydrate metabolic pathways. RES MICROBIOL 1996, 147(6-7):448-455.
57. Evans MC, Buchanan BB, Arnon DI: A new ferredoxin-dependent carbon reduction cycle in a photosynthetic bacterium. Proc Natl Acad Sci U S A 1966, 55(4):928-934.
58. Strohecker AM, White E: Autophagy promotes BrafV600E-driven lung tumorigenesis by preserving mitochondrial metabolism. AUTOPHAGY 2014, 10(2):384-385.
59. Hoque MO, Kim MS, Ostrow KL, Liu J, Wisman GB, Park HL, Poeta ML, Jeronimo C, Henrique R, Lendvai A et al: Genome-wide promoter analysis uncovers portions of the cancer methylome. CANCER RES 2008, 68(8):2661-2670.
60. Anderson NM, Mucka P, Kern JG, Feng H: The emerging role and targetability of the TCA cycle in cancer metabolism. PROTEIN CELL 2018, 9(2):216-237.
61. Cai Z, Li CF, Han F, Liu C, Zhang A, Hsu CC, Peng D, Zhang X, Jin G, Rezaeian AH et al: Phosphorylation of PDHA by AMPK Drives TCA Cycle to Promote Cancer Metastasis. MOL CELL 2020, 80(2):263-278.
62. Kovaleva OV, Romashin D, Zborovskaya IB, Davydov MM, Shogenov MS, Gratchev A: Human Lung Microbiome on the Way to Cancer. J IMMUNOL RES 2019, 2019:1394191.
63. Mouraux S, Bernasconi E, Pattaroni C, Koutsokera A, Aubert JD, Claustre J, Pison C, Royer PJ, Magnan A, Kessler R et al: Airway microbiota signals anabolic and catabolic remodeling in the transplanted lung. J Allergy Clin Immunol 2018, 141(2):718-729.
64. Conlon GA, Murray GI: Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis. J PATHOL 2019, 247(5):629-640.
65. Yan X, Yang M, Liu J, Gao R, Hu J, Li J, Zhang L, Shi Y, Guo H, Cheng J et al: Discovery and validation of potential bacterial biomarkers for lung cancer. AM J CANCER RES 2015, 5(10):3111-3122.
66. Nie C, He T, Zhang W, Zhang G, Ma X: Branched Chain Amino Acids: Beyond Nutrition Metabolism. INT J MOL SCI 2018, 19(4).
67. Burgel PR, Nadel JA: Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases. EUR RESPIR J 2008, 32(4):1068-1081.
68. Lowenmark T, Lofgren-Burstrom A, Zingmark C, Eklof V, Dahlberg M, Wai SN, Larsson P, Ljuslinder I, Edin S, Palmqvist R: Parvimonas micra as a putative non-invasive faecal biomarker for colorectal cancer. Sci Rep 2020, 10(1):15250.
69. Xu J, Yang M, Wang D, Zhang S, Yan S, Zhu Y, Chen W: Alteration of the abundance of Parvimonas micra in the gut along the adenoma-carcinoma sequence. ONCOL LETT 2020, 20(4):106.
70. Matsui A, Jin JO, Johnston CD, Yamazaki H, Houri-Haddad Y, Rittling SR: Pathogenic bacterial species associated with endodontic infection evade innate immune control by disabling neutrophils. INFECT IMMUN 2014, 82(10):4068-4079.